About Us

In order to successfully develop innovative drugs fulfilling large unmet medical needs, Oncorena is dedicated on having the right people in the right roles.


Lars Grundemar

Chief Executive Officer

MD, PhD. Former R&D leadership positions at Ferring, AstraZeneca, Novartis and Pharmacia Corporation in various countries in Europe and in the US across therapeutic areas, including Oncology. Adjunct professor Clinical Pharmacology, Lund University, Sweden.

Pål Falck

Chief Business Officer

Pharm.D, PhD, Executive Master of Management with broad background within life science. Medical affairs experience from AstraZeneca Nordics, including Nordic Medical Director role in oncology and infection. Medical advisor and business development positions in Pfizer. Former Equity Analyst within healthcare at Arctic Securities in Norway. PhD in clinical nephrology focused pharmacokinetics. Co-owner of a consultant company delivering advice and education to pharmaceutical companies and academia.